Immunai Company

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.
Technology: Artificial Intelligence, Biotechnology, Machine Learning, Therapeutics
Industry: Data Processing, End-to-end drug development
Headquarters: New York, New York, United States
Founded Date: 2018-12-01
Employees Number: 101-250
Funding Status: Early Stage Venture
Acquisitions Number: 2
Investors Number: 11
Total Funding: 295000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-10-27
Last Funding Type: Series B

Visit Website
info@immunai.com
https://www.twitter.com/Immunaitech
Register and Claim Ownership